XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.3
INVENTORY
 6 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Inventory Disclosure [Text Block]

NOTE 3 – INVENTORY

 

   

(in thousands)

  
   

As of

September 30, 2024

($)

    

As of

March 31, 2024

($)

  

Raw materials

     1,104       1,099  

Work-in-Progress

     2       -  

Finished goods

     404       441  

Total

     1,510       1,540  

 

During the six months ended September 30, 2024, and 2023, the Company wrote off approximately $2 thousand and $3 thousand of inventory due to abnormal loss due to product expiration, idle facility expense, freight, handling costs, scrap, and wasted material (spoilage). This charge was recorded in Selling, general, and administrative expenses.

 

We capitalize inventory costs related to our investigational drug, provided that management determines there is a potential alternative use for the inventory in future research and development projects or other purposes. As of September 30, 2024, and March 31, 2024, our consolidated balance sheet reported approximately $392 thousand clinical trial-related inventory, respectively.